1 mars 2023
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.53738/REVMED.2023.19.816.401
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/36876389
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pissn/1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_14DB22FD05C16
info:eu-repo/semantics/embargoedAccess , Restricted: cannot be viewed until 2024-09-01 , CC BY-NC-ND 4.0 , https://creativecommons.org/licenses/by-nc-nd/4.0/
N. Vakilzadeh et al., « Grossesse et insuffisance rénale chronique : quelle prise en charge en 2023 ? [Pregnancy and chronic renal failure: what is new in 2023?] », Serveur académique Lausannois, ID : 10.53738/REVMED.2023.19.816.401
Chronic renal failure (CRF) during pregnancy increases the risk of fetomaternal complications such as preeclampsia, premature delivery and, above all, a deterioration of renal function. A multidisciplinary preconceptional assessment is necessary in this complex clinical situation. Progress in neonatal resuscitation and a better understanding of the pathophysiological mechanisms of autoimmune nephropathy have improved the prognosis of these high-risk pregnancies. This article provides an overview of the issues related to the follow-up of pregnant women with renal disease. It summarizes the glomerular and hemodynamic physiological changes during pregnancy, the fetal and maternal risk, and the adaptation of antihypertensive and immunosuppressive drug treatments.